Source: DGNews | Posted 9 years ago
Long-Term Study Suggests Patients on a New Anti-Hypertensive May Fare Better Than Those on Most Widely-Prescribed Treatment
Tags:
Lercanidipine Acts in a Unique Way to Lower Blood Pressure While Offering Fewer Side Effects
NEW YORK, NY -- November 11, 2002 -- Forest Laboratories, Inc. (NYSE: FRX) announced that findings from a multi-center, randomized study published this month in the American Journal of Hypertension show that lercanidipine, an investigational drug for the treatment of hypertension, was significantly better tolerated than amlodipine (Norvasc
Comments